Lipocine (LPCN) Cash & Equivalents Growth (3y) (2014 - 2025)
Lipocine (LPCN) Cash & Equivalents Growth (3y) (2014 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -15.41% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 8.23% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 47.78% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -23.18% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 14.34% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 37.45% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -14.22% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -3.85% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -27.97% |
| 10 | Lipocine | 11.15 Mn | -12.76 Mn | - | -23.81% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -23.81% |
| Sep 30, 2025 | -23.56% |
| Jun 30, 2025 | -21.99% |
| Mar 31, 2025 | -21.79% |
| Dec 31, 2024 | -22.17% |
| Sep 30, 2024 | -19.66% |
| Jun 30, 2024 | -20.84% |
| Mar 31, 2024 | 16.23% |
| Dec 31, 2023 | 4.55% |
| Sep 30, 2023 | 22.82% |
| Jun 30, 2023 | 22.88% |
| Mar 31, 2023 | 23.42% |
| Dec 31, 2022 | 48.84% |
| Sep 30, 2022 | 71.68% |
| Jun 30, 2022 | 95.16% |
| Mar 31, 2022 | 71.12% |
| Dec 31, 2021 | 78.13% |
| Sep 30, 2021 | 97.00% |
| Jun 30, 2021 | 109.31% |
| Mar 31, 2021 | 22.15% |